MGD is the fastest-growing revenue opportunity in optometry. Here’s how to build a complete program — diagnostics, treatment, and biologics — with equipment that earns its keep.
MGD affects an estimated 30 million adults in the United States, and the vast majority remain undiagnosed or undertreated. That gap represents one of the largest untapped revenue opportunities in modern optometry. Patients with MGD return frequently, pay for ongoing treatment, and refer others — making lifetime patient value significantly higher than episodic refractive care.
Revenue comes from both sides of the workflow: diagnostic imaging generates billable procedures and documentation, while in-office treatments like IPL, radiofrequency, and LLLT create recurring procedural income outside of managed care. Practices that implement a structured MGD program — rather than treating it case-by-case — see measurable, sustained revenue growth and stronger patient retention.
The Equipment
A complete MGD program covers every stage of the patient journey — from initial diagnosis through active treatment and ocular surface healing. Each pillar serves a distinct clinical and financial role.
Diagnose
What it does: A 9-in-1 diagnostic platform combining meibography, non-invasive tear breakup time (NIBUT), corneal topography, tear film analysis, pupillometry, and more — everything needed to identify, stage, and document MGD disease in a single capture.
Why it matters: You cannot treat what you have not documented. Proper diagnostic imaging drives treatment compliance, justifies in-office procedures to patients, and generates billable codes independent of treatment revenue.
View Pathfinder →Treat (In-Office IPL+RF)
What it does: Dual-modality platform delivering both Intense Pulsed Light (IPL) and radiofrequency (RF) therapy for meibomian gland dysfunction. Treats the root causes of evaporative MGD with clinically validated, in-office protocols.
Why it matters: This is the primary revenue driver in a MGD program. In-office procedural treatment with strong patient retention — patients typically complete a series of sessions and return for maintenance. High per-procedure value outside of insurance constraints.
View iProElite →Treat (LLLT)
What it does: Non-invasive low-level light therapy for meibomian gland dysfunction, delivered through a comfortable mask design. Can be used as an in-office procedure or dispensed for patient home use.
Why it matters: Lower barrier to entry for practices testing the MGD market. Works well as a standalone treatment for mild-to-moderate MGD or as an adjunct to IPL/RF for enhanced outcomes. Flexible delivery model supports both in-office and take-home revenue.
View InfinityPro →Heal
What it does: Human amniotic tissue allografts designed for ocular surface repair. Supports healing in cases of severe MGD, persistent epithelial defects, post-surgical recovery, and complex ocular surface disease.
Why it matters: Biologics fill the gap that traditional treatments cannot reach. For severe and refractory cases, amniotic tissue offers a regenerative approach that differentiates your practice and serves patients who have exhausted conventional options.
View Surgenex →Program Tiers
Not every practice needs to launch with a full MGD suite. These tiers outline practical starting points based on your current patient volume, budget, and long-term goals.
Starter
For practices testing the waters. Add MGD diagnostics and a low-barrier LLLT treatment to your workflow without a major capital commitment. Build your patient pipeline and prove the economics before scaling up.
Growth
For practices ready to build MGD as a true revenue center. Full diagnostic-to-treatment flow with IPL/RF as the procedural anchor and biologics for complex cases. This is where most practices see the inflection point in MGD revenue.
Comprehensive
For practices positioning as MGD destination centers. Every diagnostic, treatment, and healing modality — plus the The Firefly S390L Digital Slit Lamp for anterior segment documentation and patient education. Maximum clinical capability, maximum revenue potential.
Building a MGD program involves multiple devices from different manufacturers, each with its own installation, training, and support requirements. Working with Carolina Optics simplifies that process.
Tell us about your practice and we'll help you design a MGD program that fits your patient population, budget, and growth goals.